RadNet IncRadNet's subsidiary DeepHealth received FDA clearance for two new AI breast imaging tools, enabling commercial deployment across RadNet centers.

DeepHealth, a wholly owned subsidiary of RadNet, has received FDA clearance for two new functionalities within its AI-powered Breast Suite. The clearances cover Breast Arterial Calcification Assessment, which automatically detects breast arterial calcifications on standard mammograms to identify potential cardiovascular disease risk, and Mammo Dx, which compares current and prior mammograms to track lesion changes and improve cancer detection. Both tools are now commercially available in the United States and will be deployed across RadNet imaging centers for real-world validation. The additions transform the Breast Suite into a fully integrated platform supporting cancer detection, cardiovascular risk assessment, breast density evaluation, and workflow optimization, currently used in over 10 million mammograms annually worldwide.
RadNet IncRadNet's subsidiary DeepHealth received FDA clearance for two new AI breast imaging tools, enabling commercial deployment across RadNet centers.
Bank of America Corp
Globus Medical
West Pharmaceutical Services IncDeepHealth received FDA clearance for two new AI breast imaging tools, making them commercially available in the US.